{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:04:19Z","timestamp":1791378259642,"version":"4.3.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["302153\/2019-5"],"award-info":[{"award-number":["302153\/2019-5"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00467-022-05683-2","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T16:04:45Z","timestamp":1658419485000},"page":"61-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review"],"prefix":"10.1007","volume":"38","author":[{"given":"Raquel Medeiros","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Henrique Mendes","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Henrique Moreira","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Antunes","family":"Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires Sara Campos","family":"de Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Gustavo Castelar","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-3882","authenticated-orcid":false,"given":"Ana Cristina","family":"Sim\u00f5es e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"5683_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.pcl.2018.02.003","volume":"65","author":"BP Dixon","year":"2018","unstructured":"Dixon BP, Gruppo RA (2018) Atypical hemolytic uremic syndrome. Pediatr Clin North Am 65:509\u2013525. https:\/\/doi.org\/10.1016\/j.pcl.2018.02.003","journal-title":"Pediatr Clin North Am"},{"key":"5683_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A (2019) Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial 23:4\u201321. https:\/\/doi.org\/10.1111\/1744-9987.12763","journal-title":"Ther Apher Dial"},{"key":"5683_CR3","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687. https:\/\/doi.org\/10.1056\/NEJMra0902814","journal-title":"N Engl J Med"},{"key":"5683_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque A-L, Licht C, Nester C, Pecoraro C, Riedl M, van deKar NCAJ, Van deWalle J, Vivarelli M, Fr\u00e9meaux-Bacchi V, for HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"5683_CR5","unstructured":"Noris M, Bresin E, Mele C, Remuzzi G (1993) Genetic atypical hemolytic-uremic syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Mirzaa GM, Amemiya A (eds) GeneReviews\u00ae. University of Washington, Seattle, Seattle (WA)"},{"key":"5683_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med 368:2169\u20132181. https:\/\/doi.org\/10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"5683_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552\u2013559. https:\/\/doi.org\/10.1056\/NEJMoa031688","journal-title":"N Engl J Med"},{"key":"5683_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S (2018) Eculizumab: a review in generalized myasthenia gravis. Drugs 78:367\u2013376. https:\/\/doi.org\/10.1007\/s40265-018-0875-9","journal-title":"Drugs"},{"key":"5683_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tmrv.2019.09.004","volume":"33","author":"CJ Patriquin","year":"2019","unstructured":"Patriquin CJ, Kuo KHM (2019) Eculizumab and beyond: the past, present, and future of complement therapeutics. Transfus Med Rev 33:256\u2013265. https:\/\/doi.org\/10.1016\/j.tmrv.2019.09.004","journal-title":"Transfus Med Rev"},{"key":"5683_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Soci\u00e9","year":"2019","unstructured":"Soci\u00e9 G, Caby-Tosi M-P, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"5683_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5683_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"5683_CR13","unstructured":"(2022) Ottawa Hospital Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 24 Feb 2022"},{"key":"5683_CR14","unstructured":"(2022) Study Quality Assessment Tools | NHLBI, NIH. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 24 Feb 2022"},{"key":"5683_CR15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan A-W, Churchill R, Deeks JJ, Hr\u00f3bjartsson A, Kirkham J, J\u00fcni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Sch\u00fcnemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"5683_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00467-014-3003-4","volume":"30","author":"E Baskin","year":"2015","unstructured":"Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O (2015) Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 30:783\u2013789. https:\/\/doi.org\/10.1007\/s00467-014-3003-4","journal-title":"Pediatr Nephrol"},{"key":"5683_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00467-020-04714-0","volume":"36","author":"V Kl\u00e4mbt","year":"2021","unstructured":"Kl\u00e4mbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, K\u00f6nig J, Vinke T, Montoya C, Lange-Sperandio B, Kirschstein M, Hennies I, Pohl M, H\u00e4ffner K (2021) Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 36:463\u2013471. https:\/\/doi.org\/10.1007\/s00467-020-04714-0","journal-title":"Pediatr Nephrol"},{"key":"5683_CR18","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00467-021-04965-5","volume":"36","author":"M Muff-Luett","year":"2021","unstructured":"Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM (2021) Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes\u2014a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 36:2349\u20132360. https:\/\/doi.org\/10.1007\/s00467-021-04965-5","journal-title":"Pediatr Nephrol"},{"key":"5683_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1159\/000510612","volume":"45","author":"AA Bamhraz","year":"2020","unstructured":"Bamhraz AA, Rahim KA, Faqeehi HY, Alanazi A (2020) Improved renal recovery with eculizumab therapy among children with high prevalence of mutation-associated atypical hemolytic uremic syndrome: a retrospective cohort study. Kidney Blood Press Res 45:939\u2013954. https:\/\/doi.org\/10.1159\/000510612","journal-title":"Kidney Blood Press Res"},{"key":"5683_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12882-016-0420-6","volume":"18","author":"N Besbas","year":"2017","unstructured":"Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F (2017) Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol 18:6. https:\/\/doi.org\/10.1186\/s12882-016-0420-6","journal-title":"BMC Nephrol"},{"key":"5683_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000487609","volume":"139","author":"N \u00c7akar","year":"2018","unstructured":"\u00c7akar N, Ozcakar ZB, Ozaltin F, Koyun M, Celikel Acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Y\u0131lmaz S, Soylemezoglu O, Yalcinkaya F (2018) Atypical hemolytic uremic syndrome in children aged <2 years. Nephron 139:211\u2013218. https:\/\/doi.org\/10.1159\/000487609","journal-title":"Nephron"},{"key":"5683_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10157-018-1610-2","volume":"23","author":"S Ito","year":"2019","unstructured":"Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S (2019) Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic\u2013uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:112\u2013121. https:\/\/doi.org\/10.1007\/s10157-018-1610-2","journal-title":"Clin Exp Nephrol"},{"key":"5683_CR23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/jpc.14390","volume":"55","author":"G Kumar","year":"2019","unstructured":"Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra MK, Ilyas SH, Al-Khasawneh E (2019) Eculizumab in paediatric atypical haemolytic uraemic syndrome: lessons learned from a single-centre experience in the United Arab Emirates. J Paediatr Child Health 55:1237\u20131240. https:\/\/doi.org\/10.1111\/jpc.14390","journal-title":"J Paediatr Child Health"},{"key":"5683_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/ckj\/sfaa062","volume":"14","author":"Palma LMP, Eick RG, Dantas GC, Tino MK dos S, de Holanda MI, the Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil)","year":"2021","unstructured":"Palma LMP, Eick RG, Dantas GC, Tino MK dos S, de Holanda MI, the Brazilian Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome Study Group (aHUS Brazil) (2021) Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab. Clin Kidney J 14:1126\u20131135. https:\/\/doi.org\/10.1093\/ckj\/sfaa062","journal-title":"Clin Kidney J"},{"key":"5683_CR25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep 4:1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"},{"key":"5683_CR26","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00431-020-03666-9","volume":"179","author":"\u0160 \u0160tolbov\u00e1","year":"2020","unstructured":"\u0160tolbov\u00e1 \u0160, Bezd\u00ed\u010dka M, Seeman T, Proh\u00e1szka Z, Csuka D, Hrachovinov\u00e1 I, Burkert J, \u0160im\u00e1nkov\u00e1 N, Pr\u016fhov\u00e1 \u0160, Zieg J (2020) Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 179:1739\u20131750. https:\/\/doi.org\/10.1007\/s00431-020-03666-9","journal-title":"Eur J Pediatr"},{"key":"5683_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10157-015-1142-y","volume":"20","author":"N Ito","year":"2016","unstructured":"Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S (2016) Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20:265\u2013272. https:\/\/doi.org\/10.1007\/s10157-015-1142-y","journal-title":"Clin Exp Nephrol"},{"key":"5683_CR28","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1177\/1076029618771750","volume":"24","author":"T Matsumoto","year":"2018","unstructured":"Matsumoto T, Toyoda H, Amano K, Hirayama M, Ishikawa E, Fujimoto M, Ito M, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Kawamura N, Ikejiri M, Kawakami K, Miyata T, Wada H (2018) Clinical manifestation of patients with atypical hemolytic uremic syndrome with the C3 p. I1157T variation in the Kinki Region of Japan. Clin Appl Thromb 24:1301\u20131307. https:\/\/doi.org\/10.1177\/1076029618771750","journal-title":"Clin Appl Thromb"},{"key":"5683_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","volume":"33","author":"KL Wijnsma","year":"2018","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM (2018) Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 33:635\u2013645. https:\/\/doi.org\/10.1093\/ndt\/gfx196","journal-title":"Nephrol Dial Transplant"},{"key":"5683_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NCAJ, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711. https:\/\/doi.org\/10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"key":"5683_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Prov\u00f4t F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.034","journal-title":"Am J Kidney Dis"},{"key":"5683_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073. https:\/\/doi.org\/10.1038\/ki.2014.423","journal-title":"Kidney Int"},{"key":"5683_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687\u2013696. https:\/\/doi.org\/10.1007\/s00467-008-0964-1","journal-title":"Pediatr Nephrol"},{"key":"5683_CR34","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859. https:\/\/doi.org\/10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol"},{"key":"5683_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Desch\u00eanes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562. https:\/\/doi.org\/10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol"},{"key":"5683_CR36","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A-L, Ville S, Pouteil-Noble C, Coindre J-P, Le Quintrec M, Rondeau E, Boyer O, Prov\u00f4t F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Ch\u00e2telet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Fr\u00e9meaux-Bacchi V (2021) Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood 137:2438\u20132449. https:\/\/doi.org\/10.1182\/blood.2020009280","journal-title":"Blood"},{"issue":"734","key":"5683_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR (2017) High risk for invasive meningococcal disease among patients receiving eculizumab Soliris despite receipt of meningococcal vaccine. Morb Mortal Wkly Rep 66(734):737. https:\/\/doi.org\/10.15585\/mmwr.mm6627e1","journal-title":"Morb Mortal Wkly Rep"},{"key":"5683_CR38","doi-asserted-by":"publisher","first-page":"e20174250","DOI":"10.1542\/peds.2017-4250","volume":"142","author":"F Martin\u00f3n-Torres","year":"2018","unstructured":"Martin\u00f3n-Torres F, Bernatowska E, Shcherbina A, Esposito S, Szenborn L, Marti MC, Hughes S, Faust SN, Gonzalez-Granado LI, Yu L-M, D\u2019Agostino D, Calabresi M, Toneatto D, Snape MD (2018) Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Pediatrics 142:e20174250. https:\/\/doi.org\/10.1542\/peds.2017-4250","journal-title":"Pediatrics"},{"key":"5683_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Soci\u00e9 G, Brodsky RA (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162:62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347","journal-title":"Br J Haematol"},{"key":"5683_CR40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00467-014-2990-5","volume":"30","author":"W Hayes","year":"2015","unstructured":"Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C (2015) Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol 30:775\u2013781. https:\/\/doi.org\/10.1007\/s00467-014-2990-5","journal-title":"Pediatr Nephrol"},{"key":"5683_CR41","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","volume":"34","author":"Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey M-A, on behalf of the Indian Society of Pediatric Nephrology","year":"2019","unstructured":"Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey M-A, on behalf of the Indian Society of Pediatric Nephrology (2019) Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol 34:1465\u20131482. https:\/\/doi.org\/10.1007\/s00467-019-04233-7","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05683-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05683-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T11:10:55Z","timestamp":1670929855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05683-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5683"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05683-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"12 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}